AN2 Therapeutics, Inc. (ANTX)
3.61
+0.47
(+14.97%)
USD |
NASDAQ |
Apr 17, 16:00
3.62
+0.01
(+0.28%)
After-Hours: 20:00
AN2 Therapeutics Cash from Investing (Quarterly) : 7.174M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Relmada Therapeutics, Inc. | -76.93M |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
| Alnylam Pharmaceuticals, Inc. | -37.17M |
| Savara, Inc. | -93.56M |
| BioMarin Pharmaceutical, Inc. | -42.45M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.236M |
| Free Cash Flow | -29.83M |
| Free Cash Flow Per Share (Quarterly) | -0.1725 |
| Free Cash Flow to Equity (Quarterly) | -5.236M |
| Free Cash Flow to Firm (Quarterly) | -5.236M |
| Free Cash Flow Yield | -27.35% |